BioPharm International Editors

Despite some progress, pharmaceutical companies have a long way to go in making their products accessible and affordable, this year's study finds.

Roche launched imCORE, a global network of cancer immunotherapy centers of excellence.

Nine fellows recognized for research ranging from cancer treatment to improved vaccines.

The agency recommended nine drugs including treatments for diabetes, hepatitis B, and HIV.

NIH researchers developed a test to identify existing drugs that might be able to combat drug-resistant bacteria.

The agreement allows Bristol-Myers Squibb exclusive license to manufacture and commercialize Nitto Denko Corporation’s NASH treatment.

The new Boston laboratory offers advanced analytical testing services.

The Broad Institute and IBM Watson Health will collaborate on a $50 million project to study how cancers become resistant to therapies.

Dedicated facility will address enhanced regulation of metals and impurities in pharmaceuticals.

GS1 US published new guidelines in preparation for the serialization and traceability requirements associated with DSCSA.

PMMI, The Association for Packaging and Processing Technologies, released a report on trends opportunities in packaging of pharmaceuticals and medical devices that predicts increased spending on capital equipment for processing and packaging.

British artificial intelligence company BenevolentAI has signed an exclusive license for a series of novel clinical-stage drug candidates with Johnson & Johnson.

The study in 48 healthy adults will assess the safety and immunogenicity of a prime-boost regime of two different intranasal doses of the RSV vaccine, SynGem.

UPS entered into a definitive purchase agreement to acquire Marken, a provider of supply-chain solutions for the life-science industry.

Researchers in the University of Dundee have discovered a new method of activating drugs to combat visceral leishmaniasis. The discovery could lead to better treatments for neglected tropical diseases.

German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.

The company invested more than €250 in production in China.

FDA puts Beijing Taiyang Pharmaceutical Industry Co. on import alert after company refuses access to inspectors.

NICE recommended eribulin for the treatment of patients with breast cancer, reversing its 2012 decision.

CFDA granted Pfizer China approval for the company’s Prevenar 13 vaccine.

Pharma industry event in Mumbai will host 40,000 visitors on Nov. 17-23.

The company announce its plans to invest $7 million in the expansion of the Westborough, MA facility.

Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.

Bellicum and Ospedale Pediatrico Bambino Gesù will collaborate on preclinical and clinical development of CAR-T and TCR therapeutics.

US and Chinese pharmacopeial standards groups commit to collaboration on standards for drug safety.

Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.

Interactive Coding Equipment has produced a detailed guide to help pharmaceutical manufacturers make informed choices in the selection of suitable coding equipment for their applications.

TraceLink launched the EU-hosted early access program to reduce the time, cost, and risk of achieving regulatory compliance for global requirements.

Teva and IBM expanded their partnership to focus on drug development and chronic disease management.

The collaboration follows the signing of a cooperative research agreement between Sanofi Pasteur, Fiocruz, and WRAIR.